ELEV - Elevation Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

2.8100

-0.7300

(-20.62%)

As of 01:51PM EDT. Market open.

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Price Crosses Moving Average

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	3.5400
Open	3.4400
Bid	2.8800 x 1400
Ask	2.9000 x 800
Day's Range	2.5500 - 3.5200
52 Week Range	0.7230 - 5.8900
Volume	2,967,707
Avg. Volume	2,019,414

Market Cap	68.389M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-3.3100
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ELEV

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli
Simply Wall St.
Private equity firms among Elevation Oncology, Inc.'s (NASDAQ:ELEV) largest shareholders, saw gain in holdings value after stock jumped 34% last week
Key Insights Elevation Oncology's significant private equity firms ownership suggests that the key decisions are...
PR Newswire
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2023, and highlighted recent business achievements.
PR Newswire
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago,
PR Newswire
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today is presenting preclinical proof-of-concept data and highlighting a clinical case study in Claudin 18.2-expressing cancers for the company's lead candidate, EO-3021. The data are being featured in an oral presentation as part of the New Drugs on the Horizon special
Zacks
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.
PR Newswire
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that preclinical proof-of-concept data for EO-3021 will be highlighted in an oral presentation at the New Drugs on the Horizon special session at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orl
PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended December 31, 2022, and highlighted recent progress.
PR Newswire
Elevation Oncology to Participate at Upcoming Investor Conferences
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that management will participate in the following investor conferences in March:
PR Newswire
Elevation Oncology to Present at the SVB Securities Global Biopharma Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 4:20 pm ET.
PR Newswire
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 9:45 am PT.
PR Newswire
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris
PR Newswire
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 11:00 am ET.
PR Newswire
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced financial results for the quarter ended September 30, 2022, and highlighted recent progress.
Insider Monkey
10 Best One Dollar Stocks To Buy Now
In this article, we discuss the 10 best one dollar stocks to buy now. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best One Dollar Stocks To Buy Now. When most people think about trading stocks, they imagine million-dollar brokers trading shares of major […]
PR Newswire
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced financial results for the quarter ended June 30, 2022, and highlighted recent progress.
PR Newswire
Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:55 am ET.
PR Newswire
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50 million senior secured loan facility from funds managed by K2 HealthVentures, a leading healthcare-focused investment firm. The initial proceeds from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Phar
PR Newswire
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting
Insider Monkey
10 Best Penny Stocks to Buy in July
In this article, we discuss the 10 best penny stocks to buy in July. If you want to see only the absolute top penny stocks to buy this month, check out 5 Best Penny Stocks to Buy in July. Penny stocks are priced under $5 and often represent high-risk public companies that do offer exponential […]